think about this initiative and where it's going. He specified in his report on this in February that "using state-of-the-art approaches to our review and inspection process means getting important new medications to patients faster." So there's more to this than just the obvious of what the initiative says. This is basically to help improve the whole area of medicine and to help the consumer.
Another one of his quotes on that day was, "FDA will focus our attention and resources on the areas of greatest risk with the goal of maximizing public health protection without impeding innovation."
Here, I have a chart which I know will be hard to read for you all. The advisory committee does have it in their handout. This is the chart of task groups within the initiative. As you can see, the steering committee oversees the activities of the various task groups. There are 14 of them on this chart. There are actually some other subgroups of these, but I'm going to go quickly through the main task groups again so you will have an idea of what we're doing under this initiative. Every one of you on the advisory committee did get a reference to